Pulmonary hypertension, Internal medicine, Cardiology, Surgery and Respiratory disease are his primary areas of study. His Pulmonary hypertension study integrates concerns from other disciplines, such as Hemodynamics, Anesthesia, Blood pressure and Pulmonary artery. His studies examine the connections between Internal medicine and genetics, as well as such issues in Endocrinology, with regards to Odds ratio and Case-control study.
Stuart Rich focuses mostly in the field of Cardiology, narrowing it down to topics relating to Asymptomatic and, in certain cases, Computed tomographic, Incidence, Mass screening and Age and gender. His Surgery research includes elements of Coronary artery disease and Connective tissue disease. His Respiratory disease research is multidisciplinary, incorporating perspectives in Cancer research, Scleroderma, Disease, Survival analysis and Cohort.
His primary areas of study are Internal medicine, Pulmonary hypertension, Cardiology, Surgery and Hemodynamics. His work on Vasodilation, Heart failure, Prostacyclin and Ejection fraction as part of general Internal medicine study is frequently connected to In patient, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them. His studies deal with areas such as Respiratory disease, Anesthesia, Intensive care medicine, Vascular resistance and Pulmonary artery as well as Pulmonary hypertension.
His work carried out in the field of Respiratory disease brings together such families of science as Chemotherapy and Pathology. Stuart Rich has researched Anesthesia in several fields, including Treprostinil and Nifedipine. The study incorporates disciplines such as Vascular disease and Blood pressure in addition to Cardiology.
Stuart Rich spends much of his time researching Internal medicine, Cardiology, Pulmonary hypertension, In patient and Heart failure. His Surgery research extends to the thematically linked field of Internal medicine. His Cardiology research integrates issues from Blood pressure and Calcium channel.
His research in Pulmonary hypertension intersects with topics in Ejection fraction, Cardiac catheterization, Cardiac output, Intensive care medicine and Levosimendan. His Heart failure study combines topics from a wide range of disciplines, such as Regurgitation, Tricuspid Valve Regurgitation and Tamponade. The various areas that Stuart Rich examines in his Pulmonary wedge pressure study include Respiratory disease and Circulatory system.
Stuart Rich mainly focuses on Pulmonary hypertension, Cardiology, Internal medicine, Heart failure and Intensive care medicine. His Pulmonary hypertension research is multidisciplinary, relying on both Exome sequencing, Wnt signaling pathway and Bioinformatics. His Cardiology study combines topics in areas such as Anesthesia, Surgery and Cohort.
His work on Hemodynamics, Pulmonary wedge pressure and Ventricular remodeling as part of general Internal medicine study is frequently linked to Pressure overload, bridging the gap between disciplines. Stuart Rich combines subjects such as Respiratory disease and Circulatory system with his study of Hemodynamics. As a part of the same scientific family, Stuart Rich mostly works in the field of Heart failure, focusing on Blood pressure and, on occasion, Atrial septostomy.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry
Gilbert E. D'Alonzo;Robyn J. Barst;Stephen M. Ayres;Edward H. Bergofsky.
Annals of Internal Medicine (1991)
A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension
Robyn J. Barst;Lewis J. Rubin;Walker A. Long;Michael D. McGoon.
The New England Journal of Medicine (1996)
PRIMARY PULMONARY HYPERTENSION: A NATIONAL PROSPECTIVE STUDY
S Rich;D R Dantzker;S M Ayres;E H Bergofsky.
Annals of Internal Medicine (1987)
Clinical classification of pulmonary hypertension
Gerald Simonneau;Nazzareno Galiè;Lewis J Rubin;David Langleben.
Journal of the American College of Cardiology (2004)
The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension.
Stuart Rich;Elizabeth Kaufmann;Paul S. Levy.
The New England Journal of Medicine (1992)
Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.
Gerald Simonneau;Robyn J. Barst;Nazzareno Galie;Robert Naeije.
American Journal of Respiratory and Critical Care Medicine (2002)
Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group
Lucien Abenhaim;Yola Moride;François Brenot;Stuart Rich.
The New England Journal of Medicine (1996)
Survival in Primary Pulmonary Hypertension The Impact of Epoprostenol Therapy
Vallerie V. McLaughlin;Alicia Shillington;Stuart Rich.
Circulation (2002)
Appetite-Suppressant Drugs and the Risk of Primary Pulmonary Hypertension
L. Abenhaim;Y. Moride;F. Brenot;S. Rich.
The New England Journal of Medicine (1996)
Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial.
David B. Badesch;Victor F. Tapson;Michael D. McGoon;Bruce H. Brundage.
Annals of Internal Medicine (2000)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
Queen's University
Northwestern University
University of California, San Diego
Duke University
University of Colorado Denver
Mayo Clinic
Columbia University
University of Paris-Saclay
University of Alabama at Birmingham
University of Bologna
Korea University
Tilburg University
University of Cambridge
Chinese Academy of Sciences
Kyoto University
Nanyang Technological University
Friedrich Miescher Institute
University of Sassari
National Institute of Chemistry
The University of Texas MD Anderson Cancer Center
Uppsala University
Washington University in St. Louis
Örebro University
University of Alabama at Birmingham
Ghent University
Erasmus University Rotterdam